Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. A new study shows that patients with tumours that are negative for estrogen receptor, progesterone receptor and human epidermal growth receptor-2 or that are HER2+/ER- appear to be most at risk from developing brain metastases. Survival is also correlated to the triple receptor status.